Clinical Trial Update: Ruxolitinib and Lenalidomide for Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of ruxolitinib and lenalidomide in patients with myelofibrosis; results were posted in 2019 after study completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Jakafi (ruxolitinib)
• Revlimid (lenalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloproliferative Diseases | Phase 2 | Status: COMPLETED | Results posted: 2019-07-31